Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 2/20 | 0.49 |
| ▸ | FKBP1A | P62942 | 7/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12890921 | 1.00 | KLK7 (0.49) | KLK7FKBP1AF2HPGDPARP1 | |
| SCHEMBL1300740 | 1.00 | KLK7 (0.49) | KLK7FKBP1AF2HPGDPARP1 | |
| SCHEMBL13601195 | 0.93 | FKBP1A (0.52) | KLK7FKBP1AF2HPGDPARP1 | |
| SCHEMBL7420306 | 0.91 | KLK7 (0.47) | KLK7FKBP1AF2HPGDPARP1 | |
| SCHEMBL9951077 | 0.91 | KLK7 (0.47) | KLK7FKBP1AF2HPGDPARP1 | |
| SCHEMBL31390581 | 0.89 | FKBP1A (0.48) | KLK7FKBP1AF2HPGDPARP1 | |
| SCHEMBL18948763 | 0.87 | FKBP1A (0.52) | FKBP1AF2HPGD | |
| SCHEMBL28816407 | 0.86 | STS (0.44) | KLK7FKBP1APARP1CTSL | |
| SCHEMBL27996466 | 0.86 | STS (0.44) | KLK7FKBP1APARP1CTSL | |
| SCHEMBL10761995 | 0.85 | FKBP1A (0.50) | FKBP1AF2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 166 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113480463-A | Synthetic method and preparation device of natural amino acid derivative | 黄淮学院 | 2021-10-08 | — | — | CN | claimed |
| CN-109912499-B | Abamebactam intermediate and preparation method thereof | 江苏奥赛康药业有限公司 | 2021-04-27 | — | — | CN | claimed |
| EP-4727546-A2 | PROTEOSOME COMPLEX INHIBITORS TARGETING CLPP1P2 PROTEASE | The Global Alliance for TB Drug Development, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20250235566-A1 | TRISLINKER-CONJUGATED DIMERIC LABELING PRECURSORS AND RADIOTRACERS DERIVED THEREFROM | Medianezia GmbH (DE) | 2025-07-24 | — | — | US | disclosed |
| US-20250122225-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2025-04-17 | — | — | US | disclosed |
| WO-2025019626-A2 | PROTEOSOME COMPLEX INHIBITORS TARGETING CLPP1P2 PROTEASE | THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. (US) | 2025-01-23 | — | — | WO | disclosed |
| US-20240382624-A1 | FIBROBLAST ACTIVATION PROTEIN TARGETED DYES THEIR RELATED USES | ON TARGET LABORATORIES INC (US) | 2024-11-21 | — | — | US | disclosed |
| US-20240299590-A1 | FIBROBLAST ACTIVATION PROTEIN TARGETED DYES THEIR RELATED USES | ON TARGET LABORATORIES INC (US) | 2024-09-12 | — | — | US | disclosed |
| US-20240238458-A1 | COMPOUNDS TARGETING FIBROBLAST-ACTIVATION PROTEIN AND METHODS OF USE THEREOF | PURDUE RESEARCH FOUNDATION | 2024-07-18 | — | — | US | disclosed |
| US-20240238458-A1 | COMPOUNDS TARGETING FIBROBLAST-ACTIVATION PROTEIN AND METHODS OF USE THEREOF | PURDUE RESEARCH FOUNDATION | 2024-07-18 | — | — | US | disclosed |
| EP-4351663-A1 | TRISLINKER-CONJUGATED DIMERIC LABELLING PRECURSORS AND RADIOTRACERS DERIVED THEREFROM | Medianezia GmbH (DE) | 2024-04-17 | — | — | EP | disclosed |
| EP-1346982-A1 | VLA-4 INHIBITORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-09-24 | — | — | EP | disclosed |
| WO-2002094799-A2 | MELANIN CONCENTRATING HORMONE RECEPTOR LIGANDS: SUBSTITUTED 1-BENZYL-4-ARYL PIPERAZINE ANALOGUES | NEUROGEN CORPORATION (US) | 2002-11-28 | — | — | WO | disclosed |
| EP-0826663-B1 | Alkynylamino acid derivatives and their use as pharmaceutical compounds | LILLY CO ELI (GB) | 2001-10-31 | — | — | EP | disclosed |
| US-6143715-A | FOR TREATING AND PREVENTION OF HEPATITIS C VIURS INFECTIONS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2000-11-07 | — | — | US | disclosed |
| EP-1012180-A2 | HEPATITIS C INHIBITOR PEPTIDE ANALOGUES | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2000-06-28 | — | — | EP | disclosed |
| EP-1003775-A2 | HEPATITIS C INHIBITOR PEPTIDES | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2000-05-31 | — | — | EP | disclosed |
| WO-1999007733-A2 | HEPATITIS C INHIBITOR PEPTIDES | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 1999-02-18 | — | — | WO | disclosed |
| WO-1999007734-A2 | HEPATITIS C INHIBITOR PEPTIDE ANALOGUES | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 1999-02-18 | — | — | WO | disclosed |
| EP-0826663-A2 | Alkynylamino acid derivatives and their use as pharmaceutical compounds | ELI LILLY AND COMPANY LIMITED (GB) | 1998-03-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240382624-A1 | FIBROBLAST ACTIVATION PROTEIN TARGETED DYES THEIR RELATED USES | FAP, FIBP, IK | KLK7 1696/4885FKBP1A 823/4885F2 458/4885 |
| US-20240238458-A1 | COMPOUNDS TARGETING FIBROBLAST-ACTIVATION PROTEIN AND METHODS OF USE THEREOF | FAP, FIBP, FGFR1 | KLK7 1770/4885FKBP1A 1257/4885F2 1262/4885 |
| US-20240299590-A1 | FIBROBLAST ACTIVATION PROTEIN TARGETED DYES THEIR RELATED USES | FAP, FIBP, IK | KLK7 1696/4885FKBP1A 823/4885F2 458/4885 |
| US-20250235566-A1 | TRISLINKER-CONJUGATED DIMERIC LABELING PRECURSORS AND RADIOTRACERS DERIVED THEREFROM | TK1, TK2, TMT1A | KLK7 2482/4885FKBP1A 782/4885F2 971/4885 |
| US-20250122225-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, SPINT2, SERPINB1 | KLK7 170/4885FKBP1A 4076/4885F2 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.